Matinas BioPharma (MTNB) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Matinas BioPharma Reports First Quarter 2021 Financial Results and Operational Highlights
May 10, 2021 6:30 AM EDTEnrollment continues in second cohort of EnACT study of MAT2203 (oral amphotericin b) in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data from second cohort anticipated Q3 2021
MAT2501 (oral amikacin) advanced into preclinical toxicology and efficacy studies; completion of Phase 1 SAD study in healthy volunteers anticipated by end of 2021
Matinas to host virtual R&D Day on June 17, 2021 to highlight LNC platform and related programs
Data from ENHANCE-IT study of LYPDISO against Vascepa® reported in Q1 2021 support continued development of LYPDISO as a potential best-in-class... More
